30 protocols found



Protocol No. Title Status
ADVL1823 Larotrectinib (LOXO-101, NSC# 788607, IND# 141824) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias Open
ALTE15N2 LEAHRN (Late Effects After High-Risk Neuroblastoma) Study Open
APEC1621B NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of JNJ-42756493 (Erdafitinib) in Patients with Tumors Harboring FGFR1/2/3/4 Alterations Open
APEC1621D NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)-Phase 2 Subprotocol of LY3023414 in Patients with Solid Tumors Open
APEC1621E NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Phase 2 Subprotocol of Selumetinib (AZD6244 Hydrogen Sulfate) in Patients with Tumors Harboring Activating MapK Pathway Mutations Open
APEC1621F NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Phase 2 Subprotocol of Ensartinib in Patients with Tumors Harboring ALK or ROS1 Genomic Alterations Open
APEC1621G NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Phase 2 Subprotocol of Vemurafenib in Patients with Tumors Harboring Braf V600 Mutations Open
APEC1621H NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Olaparib in Patients with Tumors Harboring Defects in DNA Damage Repair Genes. Open
APEC1621I NCI-COG Pediatric Match(MOLECULAR ANALYSIS FOR THERAPY CHOICE)-Phase 2 Subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes Open
APEC1621J NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)-Phase 2 Subprotocol of BVD-523FB (ulixerlinib) in Patients with Tumors Harboring Activating MAPK Pathway Mutations Open
NCI10129 A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 mutant Advanced Solid Tumors Open
NCI10222 A Phase II study of olaparib and AZD6738 in isocitrate dehydrogenase (IDH) mutant solid tumors Open
UW16034 Safety of TAS-102 in Combination with Temozolomide for Metastatic Pancreatic Neuroendocrine Tumors Open
UW17064 A Phase II, Multi-center, Open Label Study of NIR-178 in Combination with PDR001 in Patients with Selected Advanced Solid Tumors and Non-Hodgkin Lymphoma Open
UW17120 An Observational Study Profiling Biospecimens from Cancer Patients to Screen for Molecular Alterations (STRATA) Open
UW17152 An Open-Label, Phase 2 Basket Study of Neratinib in Patients with Solid Tumors with Somatic Activating HER Mutations Open
UW18059 A Phase 1/2 Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors with RET Activation (LIBRETTO-001) Open
UW18073 Treatment of CMV Infections with Viral-Specific T Cells Against CMV in Pediatric and Adult Immunocompromised Patients or Recipients of Allogeneic Stem Cell Transplantation Open
UW18113 An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors Open
UW19004 Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Open
UW19038 Symptom Cluster Experience of Cancer Patient-Caregiver Dyads Open
UW19056 Determining FDG PET/CT Repeatability in Patients with Solid Tumor Open
UW19075 A Phase 1b Study to Evaluate the Safety and Clinical Activity of AB122 in Biomarker-Selected Participants with Advanced Solid Tumors Open
UW19082 Symptom Burden, Co-Occurrence, and Trajectories in Children with Advanced Cancer Open
UW19136 A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) Open
UW19140 A Phase 1b/2, Open label, Dose Escalation and Expansion Study of the Glutaminase Inhibitor Telaglenastat (CB-839) in Combination with the CDK4/6 Inhibitor Palbociclib in Patients with Advanced or Metastatic Solid Tumors Open
UW20046 A Phase 2 Study of Futibatinib in Patients with Specific FGFR Aberrations Open
UW20069 Improving Quitline Support Study (IQS) Open
UW20070 Health Systems Reach Interventions Project Open
UW20074 Survey regarding the care of Adolescent and Young Adults (AYAs) with Cancer at the University of Wisconsin Open